Understanding how RBM10 loss affects immune response in lung cancer
Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11077772
This study is looking at how a gene called RBM10 affects non-small cell lung cancer with KRAS mutations, focusing on how its loss can make the cancer harder to treat with immunotherapy, and aims to find new ways to help improve treatment for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11077772 on ClinicalTrials.gov |
What this research studies
This research investigates the role of RBM10, a gene involved in RNA splicing, in non-small cell lung cancer (NSCLC) with KRAS mutations. It aims to understand how the loss of RBM10 leads to genomic instability and immune evasion, which can affect the effectiveness of immunotherapy treatments. The study will explore the mechanisms behind this process, including the accumulation of specific RNA structures and their impact on immune cell behavior in the tumor environment. By using advanced laboratory techniques, the research seeks to identify potential new therapeutic targets to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with KRAS-mutant non-small cell lung cancer, particularly those with RBM10 loss.
Not a fit: Patients with non-small cell lung cancer who do not have KRAS mutations or RBM10 loss may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with KRAS-mutant lung cancer by enhancing the immune response against tumors.
How similar studies have performed: Previous research has shown promising results in targeting immune evasion mechanisms in cancer, suggesting that this approach could yield significant advancements.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SKOULIDIS, FERDINANDOS — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: SKOULIDIS, FERDINANDOS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.